Your browser doesn't support javascript.
loading
Thymic Epithelial Cell Alterations and Defective Thymopoiesis Lead to Central and Peripheral Tolerance Perturbation in MHCII Deficiency.
Ferrua, Francesca; Bortolomai, Ileana; Fontana, Elena; Di Silvestre, Dario; Rigoni, Rosita; Marcovecchio, Genni Enza; Draghici, Elena; Brambilla, Francesca; Castiello, Maria Carmina; Delfanti, Gloria; Moshous, Despina; Picard, Capucine; Taghon, Tom; Bordon, Victoria; Schulz, Ansgar S; Schuetz, Catharina; Giliani, Silvia; Soresina, Annarosa; Gennery, Andrew R; Signa, Sara; Dávila Saldaña, Blachy J; Delmonte, Ottavia M; Notarangelo, Luigi D; Roifman, Chaim M; Poliani, Pietro Luigi; Uva, Paolo; Mauri, Pier Luigi; Villa, Anna; Bosticardo, Marita.
  • Ferrua F; San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Bortolomai I; Pediatric Immunohematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Fontana E; Vita-Salute San Raffaele University, Milan, Italy.
  • Di Silvestre D; San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Rigoni R; Human Genome Department, Humanitas Clinical and Research Center, Rozzano, Milan, Italy.
  • Marcovecchio GE; Milan Unit, Institute of Genetic and Biomedical Research, National Research Council (CNR), Milan, Italy.
  • Draghici E; Department of Biomedical Sciences, Institute for Biomedical Technologies-National Research Council (CNR), Milan, Italy.
  • Brambilla F; Human Genome Department, Humanitas Clinical and Research Center, Rozzano, Milan, Italy.
  • Castiello MC; Milan Unit, Institute of Genetic and Biomedical Research, National Research Council (CNR), Milan, Italy.
  • Delfanti G; San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Moshous D; San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Picard C; Department of Biomedical Sciences, Institute for Biomedical Technologies-National Research Council (CNR), Milan, Italy.
  • Taghon T; San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Bordon V; Milan Unit, Institute of Genetic and Biomedical Research, National Research Council (CNR), Milan, Italy.
  • Schulz AS; Experimental Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Schuetz C; Department of Pediatric Immunology, Hematology and Rheumatology, Necker Children's Hospital, AP-HP, Paris, France.
  • Giliani S; Laboratory "Genome Dynamics in the Immune System", INSERM UMR1163, Université de Paris, Institut Imagine, Paris, France.
  • Soresina A; Department of Pediatric Immunology, Hematology and Rheumatology, Necker Children's Hospital, AP-HP, Paris, France.
  • Gennery AR; Centre d'Etude des Déficits Immunitaires, Necker-Enfants Malades Hospital, AP-HP, Paris, France.
  • Signa S; Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Inserm UMR 1163, University Paris Descartes Sorbonne Paris Cité, Imagine Institute, Paris, France.
  • Dávila Saldaña BJ; Department of Diagnostic Sciences, Ghent University Hospital, Ghent University, Ghent, Belgium.
  • Delmonte OM; Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium.
  • Notarangelo LD; Department of Pediatrics, University Medical Center Ulm, Ulm, Germany.
  • Roifman CM; Department of Pediatrics, University Medical Center Ulm, Ulm, Germany.
  • Poliani PL; Department of Pediatrics, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Uva P; Cytogenetics and Medical Genetics Unit and "A. Nocivelli" Institute for Molecular Medicine, Spedali Civili Hospital, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
  • Mauri PL; Unit of Pediatric Immunology, Pediatrics Clinic, University of Brescia, ASST-Spedali Civili Brescia, Brescia, Italy.
  • Villa A; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Bosticardo M; Department of Pediatric Immunology and HSCT, Great North Children's Hospital, Newcastle upon Tyne, United Kingdom.
Front Immunol ; 12: 669943, 2021.
Article en En | MEDLINE | ID: mdl-34211466
ABSTRACT
Major Histocompatibility Complex (MHC) class II (MHCII) deficiency (MHCII-D), also known as Bare Lymphocyte Syndrome (BLS), is a rare combined immunodeficiency due to mutations in genes regulating expression of MHCII molecules. MHCII deficiency results in impaired cellular and humoral immune responses, leading to severe infections and autoimmunity. Abnormal cross-talk with developing T cells due to the absence of MHCII expression likely leads to defects in thymic epithelial cells (TEC). However, the contribution of TEC alterations to the pathogenesis of this primary immunodeficiency has not been well characterized to date, in particular in regard to immune dysregulation. To this aim, we have performed an in-depth cellular and molecular characterization of TEC in this disease. We observed an overall perturbation of thymic structure and function in both MHCII-/- mice and patients. Transcriptomic and proteomic profiling of murine TEC revealed several alterations. In particular, we demonstrated that impairment of lymphostromal cross-talk in the thymus of MHCII-/- mice affects mTEC maturation and promiscuous gene expression and causes defects of central tolerance. Furthermore, we observed peripheral tolerance impairment, likely due to defective Treg cell generation and/or function and B cell tolerance breakdown. Overall, our findings reveal disease-specific TEC defects resulting in perturbation of central tolerance and limiting the potential benefits of hematopoietic stem cell transplantation in MHCII deficiency.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Timo / Antígenos de Histocompatibilidad Clase II / Inmunodeficiencia Combinada Grave / Células Epiteliales / Tolerancia Inmunológica Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies País como asunto: America do norte / Europa Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Timo / Antígenos de Histocompatibilidad Clase II / Inmunodeficiencia Combinada Grave / Células Epiteliales / Tolerancia Inmunológica Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies País como asunto: America do norte / Europa Idioma: En Año: 2021 Tipo del documento: Article